SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBritish Columbia Cancer Agency
About this trial
The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.
Secondary objectives will be overall survival, progression-free survival and time to switch of next line of systemic therapy.
Radiation-related adverse events will be assess, with a specific focus on dermatitis, lymphedema and brachial plexopathy.
The exploratory objective is to correlate toxicities and outcomes with peripheral blood biomarkers and circulating tumor DNA to potentially help predict responses in future patients receiving combined therapy.
Eligibility criteria
Qualifiers
Pathologically confirmed AJCC 7th/8th edition Stage IV invasive ductal carcinoma or invasive lobular carcinoma of the breast.
Measurable disease in the breast, suitable to receive radiotherapy.
Receiving or planned to receive systemic therapy.
Patients are allowed to have SABR for oligometastatic disease as clinically indicated
Disqualifiers
Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia, pregnancy
Previous history of locoregional radiotherapy to the ipsilateral breast
Trial design
Treatments tested in this trial
- SABR
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov